Ken Bate Joins Vanda Pharmaceuticals' Board of Directors

Vanda Pharmaceuticals Inc.  (NASDAQ: VNDA) shared the news that independent biotechnology industry consultant Kenneth Bate has joined Vanda’s Board of Directors.
According to the press release:

In connection with Mr. Bate’s election, the Board has increased the number of directors to seven.
“I would like to personally welcome Ken to our Board,” said Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer of Vanda.  “We are very fortunate to have someone with his breadth of pharmaceutical industry and leadership experience on our Board as we continue to drive Vanda on a strong growth trajectory.”
Mr. Bate is an experienced biotechnology executive having led companies at various stages of development. Mr. Bate currently serves as an independent biotechnology industry consultant, which he has done since May 2009. Mr. Bate previously served as President and Chief Executive Officer of Archemix, Inc. from May 2009 to January 2012.  From 2006 to 2009, Mr. Bate served in various positions at Nitromed, Inc., most recently as President and Chief Executive Officer.  From 2002 to 2005, Mr. Bate served as Chief Financial Officer of Millennium Pharmaceuticals Inc.   Mr. Bate served as the Chairman of the Board of Cubist Pharmaceuticals, Inc. from 2011 to 2015. He currently is a director of BioMarin Pharmaceutical Inc., AVEO Pharmaceuticals, Inc., Genocea Biosciences, Inc., Catabasis Pharmaceuticals, Inc. Epizyme, Inc. and TransMedics, Inc.  Mr. Bate received his B.A. in Chemistry fromWilliams College and his M.B.A. from the Wharton School of the University of Pennsylvania.

 
Click here to read the full press release.